This content is not available in your region

Bayer eyes 16 billion euros in 2022 adjusted EBITDA

Bayer eyes 16 billion euros in 2022 adjusted EBITDA
FILE PHOTO: The logo of Bayer AG, February 24, 2014. REUTERS/Ina Fassbender/File Photo   -   Copyright  Ina Fassbender(Reuters)
Text size Aa Aa

FRANKFURT (Reuters) – German drugmaker Bayer <BAYGn.DE>, which acquired seed company Monsanto this year, said it aimed to increase adjusted core earnings to 16 billion euros (14.24 billion pounds) in 2022, up from an expected 12.2 billion euros this year.

“We will create substantial value by leveraging our innovation capabilities into growth, improved profitability and a higher cash flow. The recently announced efficiency and structural measures will further support us in these endeavors,” Chief Executive Werner Baumann said at the group’s capital markets day in London on Wednesday.

The 2022 target does not take into account the effect of currency swings.

Bayer last week announced the sale of a number of businesses, around 12,000 job cuts and 3.3 billion euros ($3.8 billion) in impairments.

(Reporting by Ludwig Burger; editing by Thomas Seythal)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.